Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …

PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly
improved overall survival (OS) and progression-free survival (PFS) compared with …

Purpose The phase III PROCLAIM study evaluated overall survival (OS) of concurrent
pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, …

Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Purpose: The goal of this study was to evaluate prospectively the engraftment rate, factors
influencing engraftment, and predictability of clinical outcome of low-passage xenografts from …

Intratumoral therapies, especially Toll-like receptor agonists, can trigger both the innate and
adaptive immune systems. BO-112 is a nanoplexed form of polyinosinic:polycytidylic acid (…

Effective development of targeted anticancer agents includes the definition of the optimal
biological dose and biomarkers of drug activity. Currently available preclinical models are not …

Patients with many advanced solid cancers have very poor prognosis, and improvements in
life expectancy are measured only in months. We have recently reported the remarkable …

BACKGROUND & AIMS: Pancreatic cancers contain exclusively tumorigenic cancer stem
cells (CSCs), which are highly resistant to chemotherapy, resulting in a relative increase in …

There is an enormous gap between the antiproliferative and in vivo antitumor efficacy of
gemcitabine in cell line-based models and its clinical efficacy. This may be due to …